Enanta Pharma Q1 2024 GAAP EPS $(1.58) Misses $(1.23) Estimate, Sales $18.00M Miss $21.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enanta Pharma (NASDAQ:ENTA) reported Q1 2024 earnings with a GAAP EPS of $(1.58), missing the $(1.23) estimate, and sales of $18.00M, missing the $21.95M estimate. This represents a decrease in both earnings and sales compared to the same period last year.
February 07, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enanta Pharma reported a larger than expected quarterly loss and a significant miss in sales for Q1 2024, indicating a decrease in performance compared to the previous year.
The reported earnings and sales miss are significant indicators of underperformance, which typically leads to negative investor sentiment in the short term. The misses in both EPS and sales, coupled with a year-over-year decrease, suggest a potential downward pressure on ENTA's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100